Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JPA Starts DispensingError/Incidents Reporting System
April 16, 2001
- Joint GL for Genetic Examinations Drafted by 8 Medical Societies
April 9, 2001
- More than 80% of Firms Demand Permission for Complete Contract Manufacturing: Survey
April 9, 2001
- Need for Public Education about Sleep Disorder Stressed: Professor
April 9, 2001
- Ono Outsources Gene Functional Analysis Project to Hitachi
April 9, 2001
- Accurate Information Needed to Overcome Bad Image of Hypnotics: Fujisawa/Sanofi-Synthelabo Seminar
April 9, 2001
- Zeria Aims at \80 Bil. Sales, Net Profit Ratio of 10% in 2005
April 9, 2001
- Taisho, Arena Tie Up for GPCR Discovery Research
April 9, 2001
- Amended Commercial Law to Accelerate Drug Industry Reorganization:Ihoken
April 9, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 9, 2001
- OTC News in Brief
April 9, 2001
- REGULATORY NEWS IN BRIEF -2-
April 9, 2001
- Aiming at Top 5 between 2005 and 2010: Mr Dunoyer of GSK
April 9, 2001
- REGULATORY NEWS IN BRIEF -1-
April 9, 2001
- Shimadzu, Eisai Codevelop Washing Validation Support System
April 9, 2001
- Sysmex Opens Technical Service Center in Africa
April 9, 2001
- Lysosome Disease Added as Designated Disease
April 9, 2001
- Yamanouchi Wants to Make Lipitor No. 1 Statin in Japan
April 9, 2001
- Nihon Schering: New in vitro Diagnostic for Rapid PSA Detection
April 9, 2001
- Public Is Not Fully Aware of Life-Style-Related Diseases: Korosho Survey
April 9, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…